Niels Hansen1. 1. Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Göttingen, Germany.
Abstract
Background: The locus coeruleus (LC) is a nucleus in the human brainstem with a variety of noradrenaline-driven functions involved in cognition, emotions, and perception. Dementia with Lewy bodies (DLB) constitutes a neurodegenerative disease involving deposits of alpha-synuclein, first appearing in the brainstem. The goal of this narrative review is to delineate the relationship between the expression of psychiatric symptoms as an early-onset of DLB and the degeneration of the LC's noradrenaline system. Methods: We searched in PubMed for relevant articles concerning LC degeneration and psychiatric symptoms in prodromal DLB in this narrative review. We rely on the McKeith criteria for prodromal psychiatric DLB. Results: We found four studies that document neuronal loss, deposits of Lewy bodies and other hints for neurodegeneration in the LC in patients with DLB. Furthermore, we reviewed theories and studies on how the degenerated noradrenaline LC system contributes to psychiatric DLB's phenotype. We hypothesized how anxiety, hallucinations, delusions, and depressive symptoms might occur in DLB patients due to degenerated noradrenergic neurons entailing consecutive altered noradrenergic transmission in the LC's projection areas. Conclusions: LC degeneration in prodromal DLB might cause psychiatric symptoms as the first and non-motor manifestation of DLB, as the LC is affected earlier by degeneration than are dopaminergic structures such as the substantia nigra, which are impaired later in the disease course.
Background: The locus coeruleus (LC) is a nucleus in the human brainstem with a variety of noradrenaline-driven functions involved in cognition, emotions, and perception. Dementia with Lewy bodies (DLB) constitutes a neurodegenerative disease involving deposits of alpha-synuclein, first appearing in the brainstem. The goal of this narrative review is to delineate the relationship between the expression of psychiatric symptoms as an early-onset of DLB and the degeneration of the LC's noradrenaline system. Methods: We searched in PubMed for relevant articles concerning LC degeneration and psychiatric symptoms in prodromal DLB in this narrative review. We rely on the McKeith criteria for prodromal psychiatric DLB. Results: We found four studies that document neuronal loss, deposits of Lewy bodies and other hints for neurodegeneration in the LC in patients with DLB. Furthermore, we reviewed theories and studies on how the degenerated noradrenaline LC system contributes to psychiatric DLB's phenotype. We hypothesized how anxiety, hallucinations, delusions, and depressive symptoms might occur in DLB patients due to degenerated noradrenergic neurons entailing consecutive altered noradrenergic transmission in the LC's projection areas. Conclusions: LC degeneration in prodromal DLB might cause psychiatric symptoms as the first and non-motor manifestation of DLB, as the LC is affected earlier by degeneration than are dopaminergic structures such as the substantia nigra, which are impaired later in the disease course.
Authors: Kimberly A Kempadoo; Eugene V Mosharov; Se Joon Choi; David Sulzer; Eric R Kandel Journal: Proc Natl Acad Sci U S A Date: 2016-12-07 Impact factor: 11.205
Authors: Ian G McKeith; Bradley F Boeve; Dennis W Dickson; Glenda Halliday; John-Paul Taylor; Daniel Weintraub; Dag Aarsland; James Galvin; Johannes Attems; Clive G Ballard; Ashley Bayston; Thomas G Beach; Frédéric Blanc; Nicolaas Bohnen; Laura Bonanni; Jose Bras; Patrik Brundin; David Burn; Alice Chen-Plotkin; John E Duda; Omar El-Agnaf; Howard Feldman; Tanis J Ferman; Dominic Ffytche; Hiroshige Fujishiro; Douglas Galasko; Jennifer G Goldman; Stephen N Gomperts; Neill R Graff-Radford; Lawrence S Honig; Alex Iranzo; Kejal Kantarci; Daniel Kaufer; Walter Kukull; Virginia M Y Lee; James B Leverenz; Simon Lewis; Carol Lippa; Angela Lunde; Mario Masellis; Eliezer Masliah; Pamela McLean; Brit Mollenhauer; Thomas J Montine; Emilio Moreno; Etsuro Mori; Melissa Murray; John T O'Brien; Sotoshi Orimo; Ronald B Postuma; Shankar Ramaswamy; Owen A Ross; David P Salmon; Andrew Singleton; Angela Taylor; Alan Thomas; Pietro Tiraboschi; Jon B Toledo; John Q Trojanowski; Debby Tsuang; Zuzana Walker; Masahito Yamada; Kenji Kosaka Journal: Neurology Date: 2017-06-07 Impact factor: 9.910
Authors: Gina R Poe; Stephen Foote; Oxana Eschenko; Joshua P Johansen; Sebastien Bouret; Gary Aston-Jones; Carolyn W Harley; Denise Manahan-Vaughan; David Weinshenker; Rita Valentino; Craig Berridge; Daniel J Chandler; Barry Waterhouse; Susan J Sara Journal: Nat Rev Neurosci Date: 2020-09-17 Impact factor: 34.870
Authors: Jordan G McCall; Edward R Siuda; Dionnet L Bhatti; Lamley A Lawson; Zoe A McElligott; Garret D Stuber; Michael R Bruchas Journal: Elife Date: 2017-07-14 Impact factor: 8.140
Authors: Matthew J Betts; Evgeniya Kirilina; Maria C G Otaduy; Dimo Ivanov; Julio Acosta-Cabronero; Martina F Callaghan; Christian Lambert; Arturo Cardenas-Blanco; Kerrin Pine; Luca Passamonti; Clare Loane; Max C Keuken; Paula Trujillo; Falk Lüsebrink; Hendrik Mattern; Kathy Y Liu; Nikos Priovoulos; Klaus Fliessbach; Martin J Dahl; Anne Maaß; Christopher F Madelung; David Meder; Alexander J Ehrenberg; Oliver Speck; Nikolaus Weiskopf; Raymond Dolan; Ben Inglis; Duygu Tosun; Markus Morawski; Fabio A Zucca; Hartwig R Siebner; Mara Mather; Kamil Uludag; Helmut Heinsen; Benedikt A Poser; Robert Howard; Luigi Zecca; James B Rowe; Lea T Grinberg; Heidi I L Jacobs; Emrah Düzel; Dorothea Hämmerer Journal: Brain Date: 2019-09-01 Impact factor: 13.501
Authors: Lilian Calderón-Garcidueñas; Angélica González-Maciel; Rafael Reynoso-Robles; Héctor G Silva-Pereyra; Ricardo Torres-Jardón; Rafael Brito-Aguilar; Alberto Ayala; Elijah W Stommel; Ricardo Delgado-Chávez Journal: Toxics Date: 2022-03-29